Holen Sie sich die Stockscreener-App
24.90
2.01%
0.49
Handel nachbörslich:
24.66
-0.24
-0.96%
Schlusskurs vom Vortag:
$24.41
Offen:
$24.3
24-Stunden-Volumen:
234.58K
Relative Volume:
0.97
Marktkapitalisierung:
$1.18B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-82.83M
KGV:
-20.06
EPS:
-1.2413
Netto-Cashflow:
$-72.22M
1W Leistung:
-9.88%
1M Leistung:
-14.14%
6M Leistung:
+8.07%
1J Leistung:
+139.42%
1-Tages-Spanne:
$24.13
$24.93
1-Wochen-Bereich:
$23.70
$28.22
52-Wochen-Spanne:
$9.80
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Firmenname
Enliven Therapeutics Inc
Sektor
Branche
Telefon
720-647-8519
Adresse
6200 LOOKOUT ROAD, BOULDER
Vergleichen Sie ELVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ELVN | 24.90 | 1.18B | 0 | -82.83M | -72.22M | -1.2413 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-29 | Eingeleitet | Jefferies | Buy |
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Enliven Therapeutics has cash runway into late 2026 - BizWest
Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
RA Capital Management, L.P. Reduces Stake in Enliven Therapeutics Inc. - GuruFocus.com
Citadel Advisors LLC Adjusts Stake in Enliven Therapeutics Inc - GuruFocus.com
COMMODORE CAPITAL LP Expands Stake in Enliven Therapeutics Inc - GuruFocus.com
Enliven Therapeutics Reports Q3 Results and Clinical Progress - TipRanks
Polar Capital Holdings Plc's Strategic Acquisition in Enliven Th - GuruFocus.com
Enliven Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
(ELVN) Investment Analysis and Advice - Stock Traders Daily
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference - StockTitan
How to Take Advantage of moves in (ELVN) - Stock Traders Daily
Jones Trading Initiates Coverage of Enliven Therapeutics (ELVN) with Buy Recommendation - MSN
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 - Investing.com
Enliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02 - MSN
Enliven Therapeutics CFO sells $24,422 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CFO sells $24,422 in stock - Investing.com
Enliven Therapeutics chief medical officer sells $24,482 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics chief medical officer sells $24,482 in stock - Investing.com India
Enliven Therapeutics COO Anish Patel sells $21,482 in stock - Investing.com
Enliven Therapeutics COO Anish Patel sells $21,482 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics' chief scientific officer sells $25,412 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CEO Kintz sells $27,722 in stock - Investing.com
Enliven Therapeutics' chief scientific officer sells $25,412 in stock - Investing.com India
Enliven Therapeutics director Heyman sells $47,104 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CEO Kintz sells $27,722 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics director Heyman sells $47,104 in stock - Investing.com India
Anish Patel Sells 716 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat
When (ELVN) Moves Investors should Listen - Stock Traders Daily
Enliven Therapeutics, Inc. (ELVN) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
ELVN stock soars to 52-week high, reaching $28.66 By Investing.com - Investing.com Australia
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 52-Week HighHere's Why - MarketBeat
Richard A. Heyman Sells 1,270 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat
Enliven Therapeutics Inc [ELVN] Insider Lyssikatos Joseph P sells 37,878 Shares - Knox Daily
Enliven Therapeutics Inc (ELVN) stock analysis: A simple moving average approach - US Post News
Financial Metrics Check: Enliven Therapeutics Inc (ELVN)’s Ratios for Trailing Twelve Months - The Dwinnex
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Update - MarketBeat
Enliven Therapeutics, Inc. Is a Great Choice for 'Trend' Investors, Here's Why - Benzinga
Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 10,420 Shares of Stock - MarketBeat
Enliven Therapeutics executive sells over $1.4 million in company stock - Investing.com India
Enliven Therapeutics director sells over $290k in company stock - Investing.com
Enliven Therapeutics director sells over $290k in company stock By Investing.com - Investing.com UK
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 5.6%What's Next? - MarketBeat
Enliven Therapeutics CFO sells over $300k in company stock By Investing.com - Investing.com South Africa
Enliven Therapeutics director sells over $77k in company stock - Investing.com India
Enliven Therapeutics director sells over $77k in company stock By Investing.com - Investing.com Canada
Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):